Notably, HIF-1α exerts protective effects against cGVHD while preserving graft-versus-leukemia (GVL) activity, offering a unique therapeutic advantage for balancing cGVHD suppression and leukemia relapse prevention. This evidence concerns the gene HIF1A and leukemia.